Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$2.98 -0.28%

-$0.02 today

Market cap
$110.83M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.07M

Average 0.07M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$25.76M

FY 2025 · Annual

Investing Cash Flow

-$542,000.00

FY 2025 · Annual

Financing Cash Flow

$25.61M

FY 2025 · Annual

-26.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Depreciation & Amortization1.17M892K972K1.33M1.53M
Deferred Income Tax00000
Stock-Based Compensation2.88M3.11M938K2.89M2.61M
Change in Working Capital(3.22M)439K(9.65M)(2.1M)(1.41M)
Accounts Receivables(2.43M)1.05M000
Inventory00000
Accounts Payables184K3.67M39K(3.76M)(334K)
Other Working Capital(979K)(4.28M)(9.69M)1.66M(1.08M)
Other Non-Cash Items(1.25M)029.36M(20.75M)145.31M
Operating Cash Flow(23.58M)(32.48M)(47.42M)(37.55M)(25.76M)
Capital Expenditures(1.3M)(2.21M)(8.14M)(1.88M)(542K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0010K00
Investing Cash Flow(1.3M)(2.21M)(8.13M)(1.88M)(542K)
Debt Repayment0054.03M34.89M25M
Common Stock Issued26.32M44.52M5K130K658K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(801K)(500K)(43K)(61K)(46K)
Financing Cash Flow25.52M44.02M53.99M34.96M25.61M
Effect of Forex Changes0(4.76M)000
Net Change in Cash639K4.56M(1.57M)(4.47M)(693K)
Free Cash Flow(24.88M)(34.69M)(55.57M)(39.43M)(26.31M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$173.8M
+ D&A$1.5M
+ Stock-Based Comp$2.6M
+ Deferred Tax$0
- Working Capital-$1.4M
+ Other Non-Cash$145.3M
= Operating Cash Flow-$25.8M
- Capex-$542.0K
= Free Cash Flow-$26.3M

Analysis

FY2025 free cash flow is -$26.3M. FCF conversion is 15.1% of net income. Operating cash flow was -$25.8M, with capex of -$542.0K. The largest bridge item is Other Non-Cash at $145.3M.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportSep 23, 2026
8-KCurrent reportSep 14, 2026
10-QQuarterly reportAug 12, 2026

Does ARMP generate free cash flow?

Armata Pharmaceuticals, Inc. (ARMP) generated -$26.30M of free cash flow in fiscal 2025.

How much operating cash flow does ARMP produce?

Operating cash flow was -$25.76M, before capital expenditures of $542,000.00.